<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03597503</url>
  </required_header>
  <id_info>
    <org_study_id>810P503</org_study_id>
    <nct_id>NCT03597503</nct_id>
  </id_info>
  <brief_title>Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment</brief_title>
  <official_title>Assessment of Efficacy and Safety of SPN-810 for the Treatment of Impulsive Aggression (IA) in Adolescent Subjects With Attention Deficit/Hyperactivity Disorder (ADHD) in Conjunction With Standard ADHD Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Supernus Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Supernus Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of SPN-810 for the treatment of impulsive
      aggression (IA) in adolescents diagnosed with ADHD when taken in conjunction with standard
      ADHD treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an addition to the ongoing pediatric studies (CHIME 1 and CHIME 2) to assess
      the efficacy and safety of SPN-810 in the improvement of impulsive aggression (IA) behaviors
      in adolescents with ADHD.

      SPN-810 will be administered in patients diagnosed with ADHD and associated feature of IA,
      who are currently being treated with an FDA-approved standard ADHD treatment and with
      persistent IA behaviors. The frequency of impulsive aggressive behaviors will be assessed as
      a primary outcome.

      .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2018</start_date>
  <completion_date type="Anticipated">December 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 29, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blind, randomized, parallel group, two-arm, placebo-controlled study with flexible dosing</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of impulsive aggression behaviors per 7 days over a period of 7 weeks</measure>
    <time_frame>7 weeks</time_frame>
    <description>The frequency of impulsive aggression behaviors will be measured using an impulsive aggression (IA) diary, developed by the sponsor as an electronic observer-reported outcome (eObsRO) instrument.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>Flexible dose of SPN-810</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be treated with flexible dose of SPN-810</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be treated with Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPN-810</intervention_name>
    <description>Flexible dose</description>
    <arm_group_label>Flexible dose of SPN-810</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Otherwise, healthy non-smoking, male and females adolescents (12-17 years of age at
             the time of screening) with a primary diagnosis of ADHD and currently taking an
             optimized FDA-approved ADHD medication.

          -  IA will be confirmed at screening using R-MOAS scale and Vitiello Aggression
             Questionnaire.

        Exclusion Criteria:

          -  History or current diagnosis of epilepsy, major depressive disorder, bipolar disorder,
             schizophrenia and other psychotic disorders, personality disorder, Tourette's syndrome
             or dissociative disorder, autism spectrum disorder, pervasive developmental disorder,
             obsessive compulsive disorder, post-traumatic stress disorder, or intermittent
             explosive disorder.

          -  Currently meeting DSM-5 criteria for pervasive developmental disorder, obsessive
             compulsive disorder, post-traumatic stress disorder or intermittent explosive
             disorder.

          -  Known or suspected intelligence quotient (IQ) &lt;70, active suicidal plan/intent or
             active suicidal thought, criminal arrest, alcohol or drug use or pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ronald Marcus, MD</last_name>
    <phone>301-838-2569</phone>
    <email>rmarcus@supernus.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>ProScience</name>
      <address>
        <city>Culver City</city>
        <state>California</state>
        <zip>90230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Bussel, MD</last_name>
      <phone>424-227-8127</phone>
      <email>marina.bussel@prosciencerg.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neuropsychiatric Research Center of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Chueh, MD</last_name>
      <phone>714-289-1100</phone>
      <email>dchueh@nrcresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MCB Clinical Research Centers, LLC</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Sedillo, MD</last_name>
      <phone>719-634-6576</phone>
      <email>asedillo@mcbcrc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center/Children's Research Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20310</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robb Adelaide, MD</last_name>
      <phone>202-476-3042</phone>
      <email>arobb@childrensnational.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32217</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nandita Joshi Jones, MD</last_name>
      <phone>904-281-5757</phone>
      <email>njoshijones@cnshealthcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meridien Research aka Florida Clinical Research Center, LLC</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Cutler, MD</last_name>
      <phone>863-940-2087</phone>
      <email>acutler@meridienresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Clinical Research Center, LLC.</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Marraffino, PhD</last_name>
      <phone>407-644-1165</phone>
      <email>amarraffino@flcrc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miami Clinical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelia Hoover, MD</last_name>
      <phone>305-443-6496</phone>
      <email>drhoover@miamiclinicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Americo Padilla, MD</last_name>
      <phone>305-598-3125</phone>
      <email>americo.padilla@qps.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of South Florida- Dept. of Psychiatry and Neurosciences</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Fallon, MD</last_name>
      <phone>813-974-2832</phone>
      <email>dfallon1@health.usf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Riesenberg, MD</last_name>
      <phone>404-881-5800</phone>
      <email>rriesenberg@acmr.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>iResearch Atlanta</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimball Johnson, MD</last_name>
      <phone>404-537-1281</phone>
      <email>drjohnson@iresearchatlanta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Capstone Clinical Research</name>
      <address>
        <city>Libertyville</city>
        <state>Illinois</state>
        <zip>60048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Greenbaum, MD</last_name>
      <phone>847-549-4214</phone>
      <email>mgreenbaum@capstoneclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AMR Conventions Research</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60563</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandeep Gaonkar, MD</last_name>
      <phone>630-983-2000</phone>
      <email>drgaonkar@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Psychiatric Associates</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Muphy, MD</last_name>
      <phone>913-438-8221</phone>
      <email>rory@murphyclinic.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hugo W Moser Research Institute at Kennedy Krieger</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Findling, MD</last_name>
      <phone>443-923-9326</phone>
      <email>RFindli1@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Charles Psychiatric Associates Midwest Research Center</name>
      <address>
        <city>Saint Charles</city>
        <state>Missouri</state>
        <zip>63304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Greg Mattingly, MD</last_name>
      <phone>636-946-8032</phone>
      <email>drmattingly@midwestresearchgroup.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alivation Research, LLC</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Duffy, MD</last_name>
      <phone>402-817-2235</phone>
      <email>drduffy@premierpsych.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hassmann Research Institute</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Hassman, DO</last_name>
      <phone>856-756-7335</phone>
      <phone_ext>666</phone_ext>
      <email>hhassman@hritrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Finger Lakes Clinical Research</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Atkinson, MD</last_name>
      <phone>585-241-9670</phone>
      <email>sda@flclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Department of Psychiatry and Behavioral Neuroscience</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caleb Adler, MD</last_name>
      <phone>513-558-2989</phone>
      <email>caleb.adler@uc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University Nisonger Center Clinical Trials Program</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugene Arnold, MD</last_name>
      <phone>614-685-7373</phone>
      <email>L.Arnold@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oklahoma Clinical Research Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peyton Lane, MD</last_name>
      <phone>405-753-4994</phone>
      <email>drpeyton@rivusinstitute.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paradigm Research Professionals</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Nixon, MD</last_name>
      <phone>405-286-2104</phone>
      <email>cnixon@researchok.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CNS Healthcare</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Arnold, MD</last_name>
      <phone>901-843-1045</phone>
      <email>varnold@cnshealthcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Physicians Medical Research Group</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Athar Haq, DO</last_name>
      <phone>817-538-9902</phone>
      <email>ahaqdo@tpmrg.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BioBehavioral Research of Austin P.C.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Divyansu Patel, MD</last_name>
      <phone>512-382-6661</phone>
      <email>dpatel@clin-edge.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gaolin Research, LLC</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Mensah, MD</last_name>
      <phone>409-331-6040</phone>
      <email>jmensah@gadolinresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Relaro Medical Trials</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zahra Tina Ali Mohammad, MD</last_name>
      <phone>4697303282</phone>
      <email>tali@relaromedical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>InSite Clinical Research</name>
      <address>
        <city>DeSoto</city>
        <state>Texas</state>
        <zip>75115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajinder Shiwach, MD</last_name>
      <phone>972-283-6286</phone>
      <email>rshiwach@aol.com</email>
    </contact>
    <contact_backup>
      <last_name>MDPA</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Houston Clinical Trials</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Katic, MD</last_name>
      <phone>713-527-8839</phone>
      <email>akatic@houstonclinitrials.com</email>
    </contact>
    <contact_backup>
      <last_name>M</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Dicovery MM Services Inc. Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77061</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolina Mbogua, MD</last_name>
      <phone>832-532-4210</phone>
      <email>drmbogua@dmmsinc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>FMCScience</name>
      <address>
        <city>Lampasas</city>
        <state>Texas</state>
        <zip>76550</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Cain, MD</last_name>
      <phone>512-556-4130</phone>
      <email>jecain@fmcscience.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Discovery MM Service, Inc. Missouri</name>
      <address>
        <city>Missouri City</city>
        <state>Texas</state>
        <zip>77459</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deirdre McMullen, MD</last_name>
      <phone>832-532-4210</phone>
      <email>drmcm@dmmsinc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Miller, DO</last_name>
      <phone>210-949-0122</phone>
      <email>jmillerdo@cttexas.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Family Psychiatry of the Woodlands</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77381</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marshall Lucas, MD</last_name>
      <phone>832-616-2674</phone>
      <email>mlucasmd@woodlandpsych.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ericksen Research &amp; Development</name>
      <address>
        <city>Clinton</city>
        <state>Utah</state>
        <zip>84015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Bostrom, MD</last_name>
      <phone>801-614-5501</phone>
      <email>medicalway@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aspen Clinical Research</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84058</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Anderson, DO</last_name>
      <phone>801-356-5555</phone>
      <email>drjandersen@aspclinic.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>July 12, 2018</study_first_submitted>
  <study_first_submitted_qc>July 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2018</study_first_posted>
  <last_update_submitted>November 22, 2019</last_update_submitted>
  <last_update_submitted_qc>November 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

